MenACWY antibody persistence study in previously vaccinated children at 40 and 60 months

Phase 2, open-label trial of Meningococcal ACWY conjugate vaccine in meningococcal disease (2 cohorts), sponsored by Novartis. Primary endpoints: Percentage of participants with hSBA titers greater than or equal to 1:8 for serogroups A, C, W-135, and Y, Percentage of participants with hSBA titers greater than or equal to 1:4 for serogroups A, C, W-135, and Y and 1 more. Started Nov 2007; status: completed.